#USA #Scottsdale #Syantra #Vincere Cancer #Onco-ID Breast

Groundbreaking Clinical Trials at Vincere Cancer Center

Vincere Cancer Center, located in Scottsdale, Arizona, has initiated recruitment for clinical studies aimed at evaluating a new breast cancer screening technology. This innovative initiative is in collaboration with Syantra, Inc., a pioneering biotechnology firm specializing in cutting-edge cancer detection methodologies.

The focus of this study is Syantra's Onco-ID™ Breast test, which utilizes a multi-target whole blood mRNA approach. This advanced test is designed specifically for women at elevated risk of developing breast cancer. The clinical trials are funded through the Congressionally Directed Medical Research Program (CDMRP) and aim to generate robust evidence that supports the clinical implementation and market access of the Onco-ID Breast test in the U.S. population.

The Importance of Early Detection

Breast cancer continues to rise in incidence among younger women, particularly those with dense breast tissue, which affects nearly half of all women. Traditional methods such as mammography can struggle to detect cancers in these cases. Early detection is critical, as breast cancer has a staggering 99% five-year survival rate when diagnosed at the earliest invasive stage. The statistics, however, are alarming—despite a notable 43% reduction in breast cancer mortality between 1989 and 2020, an estimated 43,250 lives are expected to be lost to the disease in the U.S. this year alone.

The Role of Onco-ID Breast

The Onco-ID Breast test represents a significant leap forward in breast cancer detection technology. It employs a combination of mRNA biomarkers, specialized reagents, and machine learning algorithms to identify breast cancer in hyper-early stages. This multifaceted approach could complement existing screening guidelines, offering a potent new tool for medical professionals.

Dr. Massimo Cristofanilli, a professor at Weill Cornell Medicine, emphasizes the necessity of such advancements, stating that early-stage detection remains a challenge for many women, especially those with dense breast tissue. A simple blood test could lead to earlier diagnoses and, ultimately, better patient outcomes.

Collaborative Approach

The clinical study brings together a collaborative team of experts including Dr. Cristofanilli and Professor Kristina Rinker from the University of Calgary, alongside Dr. Vershalee Shukla at Vincere Cancer Center. This diverse alliance of medical professionals aims to implement the Onco-ID Breast test through a longitudinal, non-interventional multicenter study that will involve around 2,000 women aged between 30 to 75 who are at high risk for breast cancer.

Furthermore, this initiative will examine how a participant's ethnicity, geographic location, and personal characteristics might affect the performance of the breast cancer test. Such insights could pave the way for future improvements and broader access to innovative cancer critical testing technologies.

Community Impact

Vincere Cancer Center’s commitment to enhancing cancer detection accessibility is laudable. As the first site to initiate participant recruitment for this promising study, the center is positioning itself as a leader in the fight against breast cancer within its community. Doctor Shukla stated, "Onco-ID Breast has the potential to deliver earlier identification of breast cancer, particularly for women in remote areas who may not have regular access to screening services."

Syantra's test is built upon a patented platform that captures signals from the body's immune system, thereby detecting an active cancer signature. This is accomplished by analyzing gene expressions through a custom multiplexed qPCR process alongside machine learning-derived software algorithms.

The Future of Breast Cancer Detection

With the Onco-ID Breast test at the forefront of precision oncology, Vincere Cancer Center, in partnership with Syantra, stands to make significant strides towards improving breast cancer detection methods. The clinical trials, which are expected to run for an extensive timeline, are a testament to the ongoing pursuit of advancements in cancer care and detection technologies.

For those interested in participating or learning more about the study, additional information can be found at Syantra's website.

About Vincere Cancer Center

Founded in 2017, Vincere Cancer Center offers a holistic and innovative approach to cancer care, emphasizing early detection and precision medicine. The center's commitment to advancing cancer treatment and technology is matched by its dedication to patient care and outcomes.

About Syantra

Established by a dedicated team of biomedical engineers and medical professionals, Syantra Inc. is revolutionizing cancer detection through its innovative technologies, aiming to reshape how cancer is approached in clinical practice. Their commitment to excellence ensures they are at the cutting edge of precision biotechnology.